The global Donohue syndrome treatment market garnered a market value of US$ 17 Billion in 2023 and is expected to accumulate a market value of US$ 25 Billion by registering a CAGR of 4% in the forecast period 2023 to 2033. The increasing focus on research and the development of innovative therapeutic medications has raised the market value of rare disease treatments and is anticipated to drive the market.
The usage of technologically driven new instruments in the detection of uncommon genetic illnesses is expanding as product development continues. Favorable government policies aiming at increasing public knowledge of rare illness medications are increasing the adoption of effective therapies for Donohue syndrome. Donohue syndrome is a rare autosomal recessive insulin resistance illness that causes a functional deficiency in insulin receptor activity and affects the capacity of insulin to bind to the receptor. Severe hyperinsulinism and fasting hypoglycemia are symptoms, as is severe failure to thrive despite feeding. Fasting over an extended period of time causes muscular atrophy, reduced subcutaneous fat, and an excess of thick skin.
A decrease in thoracic diameter is exacerbated by greater abdominal distension, which has an effect on respiratory reserve. The cardiac illness appears early in childhood, with hyperinsulinism causing progressive hypertrophic cardiomyopathy. The prognosis is terrible, with the majority of patients dying of sepsis in infancy. The market's growth drivers include an increase in the number of Donohue syndrome treatment cases worldwide, favorable government policies, an increasing number of new medication releases, and increased R&D efforts for innovative therapies and pharmaceuticals.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 17 Billion |
| Anticipated Forecast Value (2033) | US$ 25 Billion |
| Projected Growth Rate (2023 to 2033) | 4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for Donohue syndrome treatment is projected to increase at a CAGR of 4% during the forecast period between 2023 and 2033, reaching a total of US$ 25 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3.5%.
Technological advancements like NGS and microarray are important market drivers. The drop in sequencing prices has shifted focus to testing for rare disorders. Increased need for early and speedy diagnosis is likely to drive market expansion. The vital role of translational research and genomic technologies in improving the analysis and detection of new mutations is predicted to contribute to the expansion of the sector.
Growing Number of Healthcare Providers to Drive the Market
The Donohue syndrome treatment market is expanding due to the rising number of healthcare providers and the increasing prevalence of diabetes. Insulin resistance is a disease in which cells do not react appropriately to the hormone insulin. Insulin is a hormone that lets glucose into cells while simultaneously lowering blood glucose levels.
The pancreas produces insulin in reaction to carbohydrates in the diet. In insulin resistance, the same quantity of insulin has a different effect on glucose transport and blood sugar levels. Diabetes develops when glucose levels rise due to resistance and compensatory insulin production fails. Diabetes diagnosed for the first time during pregnancy is known as gestational diabetes.
Gestational diabetes, like other kinds of diabetes, impacts the way cells use sugar. Gestational diabetes produces excessive blood sugar levels, which can have an impact on pregnancy and the health of the baby. As a result, the Donohue syndrome treatment market is expanding.
Growing Prevalence of Diabetes as well as Sedentary Lifestyle to Surge up Demand for Donohue Syndrome Treatment
The rising incidence of diabetes, combined with an increase in a sedentary lifestyle, is fuelling the expansion of the Donohue syndrome treatment market. Sedentary lifestyles are becoming more common as the population ages, and obesity is becoming more prevalent, increasing the number of people suffering from insulin resistance. Worries are compounded by the adoption of a sedentary lifestyle as a result of less physical activity.
The glucose tolerance test is a medical test in which glucose is administered and blood samples are obtained to measure how quickly the glucose is removed from the blood. The test is often used to screen for diabetes, insulin resistance, decreased beta cell function, reactive hypoglycemia, acromegaly, and other uncommon carbohydrate metabolism diseases. As a result, the Donohue syndrome treatment market is expanding.
Principal Consultant
High Expenditures associated with Donohue Syndrome Treatment Research and Development
Despite growing global attention on the research and commercialization of rare illness treatments like Donohue syndrome treatment, several obstacles are impeding the market growth. Drug costs rise because of the high expense of studying and developing pipeline candidates for the treatment of Donohue syndrome treatment.
The high expense of therapies has severely hindered their widespread acceptance, particularly in underdeveloped nations. Such high treatment costs are also a subject of worry in developed nations, as many treatments may not be appropriately reimbursed, raising the patient's out-of-pocket expenditures dramatically.
Impactful Government Initiatives to Widen Profit Margins
The Asia Pacific area is expected to increase rapidly over the projected period of 2023 to 2033. The initiatives taken by Asia Pacific area governments to assist persons suffering from orphan illnesses are to blame for the spread.
The successful execution of health policies meant to treat patients with orphan diseases by the governments of various Asia-Pacific nations is also expected to have a substantial impact on the Donohue syndrome treatment market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3.5% in the assessment period 2023 to 2033.
Better Healthcare Structure to Accelerate Market Growth
North America will provide the most prospects for growth for players in the Donohue syndrome treatment industry. Drugs for Donohue syndrome treatment are in the last phases of clinical testing and are scheduled to be marketed over the projected period, according to vendors in the region.
This, combined with the availability of an installment-based payment mechanism, will contribute to the expansion of the market for Donohue syndrome treatment in North America. North America is expected to grow at a CAGR of 3.9% in the assessment period 2023 to 2033.
Hefty Investments by Regional Market Participants to Bring Plethora of Opportunities
The adoption of more modern home healthcare technology, as well as the advent of novel value-based payment and service models, has generated a valuable investment opportunity in UK healthcare. As the nation's healthcare business grows, regional market participants are investing extensively in the development of sophisticated Donohue syndrome treatment in the zone.
The UK fosters investment and encourages innovation in the healthcare, life sciences, and technology sectors through R&D corporate tax reduction. As a result, suppliers are investing significantly in Europe. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 3.6% in the assessment period 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Insulin Pump Therapy Segment to enhance Sales Prospects
Due to its ease of use, the insulin pump therapy segment is likely to grow significantly. The simplicity of usage, rising junk food consumption, and the increased acceptance of a sedentary lifestyle are expected to be other significant factors driving the segment’s growth further fueling the market growth.
The Hospitals Segment to Rule the Market during the Forecast Period
The market is segmented into hospitals, clinics, and others based on the end users. The hospital segment is predicted to hold the biggest market share over the projection period. The main reason for this dominance is that many medications must be delivered intravenously by qualified healthcare workers in hospitals.
Key start-up players in the Donohue syndrome treatment are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Donohue syndrome treatment start-ups are as follows:
Key players in the Donohue syndrome treatment market are Medtronic plc, Hoffmann-La Roche Ltd, Tandem Diabetic Care, Inc., Insulet Corporation, Ypsomed, Sooil Development, JingasuDelfu Co., Ltd., Becton Dickinson and Company, Braun Melsungen AG and Sanofi.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 17 Billion |
| Market Value in 2033 | US$ 25 Billion |
| Growth Rate | CAGR of 4% from 2023 to 2033 |
| Base Year for Estimation | 2021 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The top market players are A&B, Nutri Pea, and Archer Daniels.
The market is valued at US$ 17 billion in 2023.
Adoption of the treatment is estimated to be worth US$ 25 billion by 2033.
North America dominates the market and could witness a 3.9% CAGR through 2033.
Simplicity in the use of insulin pump therapy makes it the leading market segment.
1. Executive Summary | Donohue Syndrome Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. IGF-1 Therapy
5.3.2. Insulin Pump Therapy
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End User
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Treatment
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End User
13.6. UK
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Medtronic plc
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Hoffmann-La Roche Ltd
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Tandem Diabetic Care, Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Insulet Corporation
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Ypsomed
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Sooil Development
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Jingasu Delfu Co., Ltd.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Becton Dickinson and Company
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Braun Melsungen AG
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Sanofi
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Donohue Syndrome Treatment Market
